Together with our clients, we accelerate innovations to improve healthcare.

Contact us

Co-Innovation & Development

Build a solid business case from your research and product development by optimising your innovation to meet user and market needs.


International Business Development

Discover market trends and business opportunities and create new solutions by putting your customer at the centre of your business model and product prototyping.


Innovation Procurement Support

Explore opportunities to develop innovative solutions by procuring research and development (R&D) services.


our services


You have the research, technology and ideas for innovation; we support your way to bring it successfully to your customers.

Co-Innovation & Development



More Info

Transforming research into innovation requires multidisciplinary collaboration between academics, companies, and public organisations. 

Deciding whether the innovation is ready for commercialisation requires feasibility studies to yield information on, e.g. technology readiness level (TRL), patentability, market viability, and funding needs.

Feasibility studies can be categorised according to:

  • Scientific and technological feasibility
  • Market feasibility
  • Financial feasibility

A comprehensive perspective on the scientific and technological aspects of the innovation is required to define implementation routes to create a roadmap through the different stages of development.

One of the most important aspects is to identify the product-market fit and freedom to operate (FTO) to have a reliable outlook for the business potential of the specified target market.

However, the deciding factor is the financial capacity needed to commercialise the product, where available public funding usually determines the first steps before investors and other funding resources can be considered.

Safe by Design

More Info

Designing for inherent safety is one of the most fundamental requirements for medical innovations involving a patient/user-centric design model to ensure that the design minimises patient/end-user hazards or any use-related risks.

To create an effective design control procedure, a well-established Quality Management System (QMS) in compliance with ISO 13485, ISO 14971, and FDA CFR Title 21 part 820 is a prerequisite.

Defining the requirements for design safety begins in the discovery phase with user research and specification using Human Factors Engineering (HFE) and usability engineering process according to the IEC 62366 family of standards alongside risk-based identification of hazards according to ISO 14971.

The risk-based design and evaluation continue in the design verification and validation process, which is crucial in demonstrating that user needs and intended uses are met and ensuring that the innovation gets regulatory approval.

Design safety affects the whole life cycle of an innovation, and post-market surveillance provides the most thorough user feedback to improve safety issues.

Clinical Design

More Info

Bringing innovation to clinical design is one of the most fundamental parts of the development process and requirements for market authorisation. It involves experimental design in medical and epidemiological research and the design of clinical investigation in several stages.

Deciding whether an innovation is ready for clinical evaluation requires extensive preclinical studies that yield preliminary data on e.g. efficacy, biocompatibility, and safety.

Depending on the innovation, preclinical studies may involve studies on biomedical engineering, in vitro and in vivo studies, and silico modelling.

The clinical investigation of medical devices comes with specific challenges as each design is unique and specific for indication and user profile.

The clinical investigation of pharmaceuticals should be adequate and well-controlled, requiring particular attention to ensure the appropriateness of the clinical design to determine whether there is substantial evidence to support the claims of effectiveness.

The aim is to guide innovation successfully through the different types/phases of clinical evaluations.


More Info

The health industry is a highly regulated environment for research, development, and market authorisation.

Compliance affects the whole life cycle of the innovation, aiming to ensure quality, safety, effectiveness, and performance as stipulated by applicable legislation, regulations, and standards for their target markets.

To demonstrate compliance, manufacturers must meet the requirements set forth by regulatory agencies, such as implementing an adequate quality management system, establishing appropriate development procedures and post-market surveillance, and demonstrating clinical evidence.

International Business Development


Internationalization Potential Analysis

More Info

Internationalisation and market expansion take resources from any business. However, strategic planning becomes even more complex and demanding in the case of the health sector.

Health care is local and will always remain local. Consequently, any internationalisation effort will face obstacles such as local perceptions, preferences, and legislation affecting the safety of the design, treatment procedures, and market authorisation, to name a few.

Given these premises, it is crucial to identify the needs and trends of the target market to find a fit between the product and the market, and creating market share depends on the insights gained from competitors’ products, sales, and marketing strategies.

The team’s core competencies have to meet the needs of the internationalisation efforts, and financial capacities should be well analysed to be adequately prepared for market accession.

Business Alignment

More Info

One of the most essential aspects of developing a market entry strategy is ensuring that the company’s policies align with the target market’s legislation and local business practices.

In the case of the health industry, this means discovering the correct regulatory pathways to acquire market authorisation and designing reimbursement strategy, but also ensuring that intellectual property rights and freedom to operate issues are clarified.

For healthcare innovation, there is also the question of whether clinical evaluations are required for market accession, to what extent it is feasible to conduct them, and how they can be used in assessing the pricing model.

Market Entry Strategy

More Info

Bringing healthcare innovations to international markets raises many issues about their type, user profile, and indications, which need consideration when outlining a strategy.

A successful strategy for market entry should be well implementable, considering available resources financially and team competencies, with well-defined objectives appropriate for the target market.

The key factor is to find the right partner, be it a joint venture, licensing, exporting, or any innovative strategy to build a business model to achieve sustainable growth.
One of the essential points is to create a feasible reimbursement strategy in the context of the legislation to secure revenues and stay ahead of competitors.

Growth Strategy

More Info

Identifying and overcoming common pitfalls associated with growth is essential if your business is to continue to grow and succeed. Finding suitable instruments to scale up the business from funding to international partnerships will help in ensuring future success.

Preparing for future market challenges is crucial to growing revenues and market share, and business expansion requires continuous assessment of business performance and identification of areas for improvement.

Keeping up with the market trends, opportunities, and competitors is essential for strategic planning for growth, as is managing financial flows and creating suitable systems and team competencies.

Innovation Procurement Support


Strategic Outlook and Demand Identification

More Info

Businesses implementing innovation procurement are often more forward-looking and strategic, forcing them to think of their future innovation needs.

Having a clear picture of upcoming innovation needs is a pre-condition for the actual implementation of innovation procurement, as the solution has to have the potential to overcome the challenge of wide adoption by the public or private sector.
Understanding the solutions available on the market allows for determining the most appropriate procedure.

If the desired solution is unavailable on the market or requires advanced technology, or if the solution already exists but may need improvements and support for its launch on the market, innovation procurement may present an appropriate instrument.

European Innovation Council (EIC)

More Info

The EIC aims to identify and support high-risk and high-potential innovative SMEs and start-ups with breakthrough technologies and game-changing innovations with the potential to scale up internationally and drive economic growth.

All stages of innovations are supported by research and development on the scientific underpinnings, demonstration of breakthrough technologies and innovations to meet real-world needs, and the scaling up of start-ups and small and medium-sized enterprises (SMEs). 

The EIC provides financial support through three main funding schemes:

  • EIC Pathfinder is an instrument for advanced research on breakthrough technologies.
  • EIC Transition is an instrument for transforming research results into innovation opportunities.
  • EIC Accelerator is an instrument for individual start-ups/SMEs to develop and scale up breakthrough innovations with high risk and high impact.

Non-Dilutive Financing

More Info

Non-dilutive financing is a critical component of the strategic financing mix for innovative start-ups and SMEs in the Life Science, MedTech, and Health industries to cover the high-risk, lengthy, and costly development paths toward market authorisation.

When other financial sources are out of reach due to the high risk and unforeseen challenges involved in the early development stages, non-dilutive financing provides a critical component to raising funding without giving away any ownership of the company itself and building value at the same time to future equity investors.

Types of non-dilutive funding to consider

  • Government Research Grants, such as the Horizon Europe program, EIC Pathfinder, Innovative Medicine Initiative, and EU Mission: Cancer, among others.
  • Government Industry Grants, such as Horizon Europe, EIC Accelerator, and Eureka, among others.
  • Non-profit organisations include the Human Frontier Science Program (HSFP) and the European Science Foundation (ESF), among others.

Unique Insights

Long-established expertise in doing business between Europe and East Asia.

Network of Experts

Expertise at the intersection of biomedical research and technological implementation.

Free Consultation

Presentation of the project with expectations and needs for evaluation.



Our clients and partners are driven by the common mission to bring breakthrough technology, and cutting-edge innovations to improve healthcare.

Research Groups

More Info
  • EU project facilitation & partnerships
  • EIC procurement support
  • Spin-out guidance & support
  • Feasibility
  • Co-development from TRL0 to TRL9

Spin-Outs & Start-Ups

More Info
  • EU project facilitation & partnerships
  • EIC procurement support
  • Co-development from TRL0 to TRL9
  • Business & funding strategies
  • International market access strategies


More Info
  • International business strategies
  • Export development & strategies
  • International partnerships
  • Biomedical technology consulting


More Info
  • Health industry consulting
  • Technology portfolio consulting
  • Company introductions



Biokatu 12, FinnMedi 5

33520 Tampere